Tags

Type your tag names separated by a space and hit enter

Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience.
Clin Cardiol. 2018 Jan; 41(1):159-165.CC

Abstract

There is considerable evidence for the role of low-density lipoprotein cholesterol (LDL-C) in the development of atherosclerotic cardiovascular disease. Although statin therapy remains the most frequency prescribed medication to reduce LDL-C and lower risk of cardiovascular disease, a considerable number of patients develop muscle-related side affects. This review summarizes recent literature supporting the role of nutraceuticals as LDL-C-lowering therapy in statin-intolerant patients, with evidence from our own clinical practices.

Authors+Show Affiliations

School of Medicine, Faculty of Health & Medical Sciences, University of Western Australia, Perth. School of Biomedical Sciences and Curtin Health Innovation Research Institute, Perth, Australia.School of Medicine, Faculty of Health & Medical Sciences, University of Western Australia, Perth. Lipid Disorders Clinic, Department of Cardiology, Royal Perth Hospital, Perth, Australia.School of Medicine, Faculty of Health & Medical Sciences, University of Western Australia, Perth. Perth Lipid Clinic, Primary Care, Perth, Australia.School of Medicine, Faculty of Health & Medical Sciences, University of Western Australia, Perth. Lipid Disorders Clinic, Department of Cardiology, Royal Perth Hospital, Perth, Australia.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29363784

Citation

Ward, Natalie C., et al. "Nutraceuticals in the Management of Patients With Statin-associated Muscle Symptoms, With a Note On Real-world Experience." Clinical Cardiology, vol. 41, no. 1, 2018, pp. 159-165.
Ward NC, Pang J, Ryan JDM, et al. Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience. Clin Cardiol. 2018;41(1):159-165.
Ward, N. C., Pang, J., Ryan, J. D. M., & Watts, G. F. (2018). Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience. Clinical Cardiology, 41(1), 159-165. https://doi.org/10.1002/clc.22862
Ward NC, et al. Nutraceuticals in the Management of Patients With Statin-associated Muscle Symptoms, With a Note On Real-world Experience. Clin Cardiol. 2018;41(1):159-165. PubMed PMID: 29363784.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience. AU - Ward,Natalie C, AU - Pang,Jing, AU - Ryan,Jacqueline D M, AU - Watts,Gerald F, Y1 - 2018/01/24/ PY - 2017/10/09/received PY - 2017/11/16/revised PY - 2017/11/21/accepted PY - 2018/1/25/pubmed PY - 2018/8/23/medline PY - 2018/1/25/entrez KW - Low-Density Lipoprotein Cholesterol KW - Nutraceuticals KW - SAMS KW - Statin Myopathy SP - 159 EP - 165 JF - Clinical cardiology JO - Clin Cardiol VL - 41 IS - 1 N2 - There is considerable evidence for the role of low-density lipoprotein cholesterol (LDL-C) in the development of atherosclerotic cardiovascular disease. Although statin therapy remains the most frequency prescribed medication to reduce LDL-C and lower risk of cardiovascular disease, a considerable number of patients develop muscle-related side affects. This review summarizes recent literature supporting the role of nutraceuticals as LDL-C-lowering therapy in statin-intolerant patients, with evidence from our own clinical practices. SN - 1932-8737 UR - https://www.unboundmedicine.com/medline/citation/29363784/Nutraceuticals_in_the_management_of_patients_with_statin_associated_muscle_symptoms_with_a_note_on_real_world_experience_ L2 - https://doi.org/10.1002/clc.22862 DB - PRIME DP - Unbound Medicine ER -